Tag Archives: NASDAQ:KPTI

Analysts’ Top Healthcare Picks: KPTI, BLUE

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI) and Bluebird Bio (NASDAQ: BLUE) with bullish sentiments. Karyopharm Therapeutics (NASDAQ: KPTI) H.C. Wainwright analyst Edward White maintained

H.C. Wainwright Believes Karyopharm Therapeutics (NASDAQ: KPTI) Won’t Stop Here

H.C. Wainwright analyst Edward White assigned a Buy rating to Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $30. The company’s shares opened today at $18.59, close to its 52-week high of $18.93. According to TipRanks.com, White

Cantor Fitzgerald Sticks to Their Buy Rating for Karyopharm Therapeutics

Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $18. The company’s shares opened today at $13.08. Goldstein commented: “KPTI reported top-line STORM data, which demonstrated a 25.4%

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Intuitive Surgical (NASDAQ: ISRG)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Karyopharm Therapeutics (NASDAQ: KPTI) and Intuitive Surgical (NASDAQ: ISRG). Karyopharm Therapeutics (NASDAQ: KPTI) Canaccord Genuity analyst Arlinda Lee reiterated a Buy rating on

Karyopharm Therapeutics Receives a Buy from Canaccord Genuity

Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $22. The company’s shares opened today at $12.76. According to TipRanks.com, Lee is a 4-star analyst with an average

Analysts Are Bullish on These Healthcare Stocks: KPTI, PTLA

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Karyopharm Therapeutics (NASDAQ: KPTI), Portola Pharma (NASDAQ: PTLA) and Shire (NASDAQ: SHPG) with bullish sentiments. Karyopharm Therapeutics (NASDAQ: KPTI) In a report